Related Experiment Video
Updated: Aug 17, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Role of sonic hedgehog ligand in gastric cancer therapeutics
Kulsum Akhtar1, Irfan Maqbool1, Gulzar Ahmad Bhat1
1Department of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
Purpose:
The abnormal activation of the sonic hedgehog (SHH) signaling pathway is responsible for the progression of several types of cancers including Gastric Cancer (GC). SHH has been associated with the activation of different signaling pathways. Therefore, in this study, we investigated messenger RNA (mRNA) and protein expression of SHH in gastric malignancies and possible correlation with various clinicopathological parameters.
Materials And Methods:
A total of 53 surgically resected tumors and adjacent histologically normal tissues from GC patients were investigated in study subjects. A quantitative real-time polymerase chain reaction and immunohistochemistry methods were used for expression analysis of SHH.
Results:
At mRNA level, SHH was overexpressed in 60% (27/45) of GC cases as compared to their adjacent normal tissues. SHH immunohistochemical analysis revealed abundant cytoplasmic localization and overexpression in 43.39% (23/53) of GC tissues. SHH overexpression was not associated with any of the clinicopathological parameters.
Conclusion:
Our results showed that SHH is dysregulated in GC and might be considered as a biomarker for GC progression and can be used as a target in cancer therapeutics.
Insights
Sonic hedgehog (SHH) signaling pathway is abnormally activated in gastric cancer (GC). SHH is overexpressed in GC tissues, suggesting its potential as a biomarker and therapeutic target for gastric cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- The sonic hedgehog (SHH) signaling pathway plays a critical role in embryonic development and is implicated in the progression of various cancers, including Gastric Cancer (GC).
- Aberrant SHH pathway activation is linked to the development and advancement of GC, highlighting its significance in gastric tumorigenesis.
Purpose of the Study:
- To investigate the messenger RNA (mRNA) and protein expression levels of SHH in gastric cancer tissues.
- To explore the correlation between SHH expression and clinicopathological parameters in patients with GC.
Main Methods:
- Analysis of SHH mRNA and protein expression in 53 surgically resected GC tumors and adjacent normal tissues.
- Quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were employed for expression analysis.
Main Results:
- SHH mRNA was overexpressed in 60% of GC cases compared to normal tissues.
- SHH protein overexpression was observed in 43.39% of GC tissues, with abundant cytoplasmic localization.
- No significant association was found between SHH overexpression and clinicopathological parameters.
Conclusions:
- SHH is dysregulated in gastric cancer, indicating its potential role in GC progression.
- SHH may serve as a valuable biomarker for gastric cancer.
- Targeting the SHH pathway presents a potential therapeutic strategy for gastric cancer treatment.
More Related Videos
09:03Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
09:24Combined Conditional Knockdown and Adapted Sphere Formation Assay to Study a Stemness-Associated Gene of Patient-derived Gastric Cancer Stem Cells
Published on: May 9, 2020
Related Concept Videos
Hedgehog Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Mitogens and the Cell Cycle
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...